A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas (GBM), the most deadly form of brain tumors.
Otsuka terminates Alzheimer’s agitation drug after failed Phase 3
Otsuka ended development of AVP-786 after the experimental Alzheimer’s disease treatment failed a late-stage study earlier this year. The company made the decision to terminate